Pancreatic Cancer Research

ResearcherJikei University School of MedicineActive in the last 2 years

Shinji Onda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6741-2796; OpenAlex author ID A5060758866. Sources: OpenAlex.

Their work

Papers
29 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2012: 2 papers · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 3 papers · 2022: 3 papers · 2023: 5 papers · 2024: 5 papers · 2025: 7 papers · 2026: 3 papers

Papers 29

  1. The Goddard score for emphysema predicts the postoperative prognosis in pancreatic cancer. Co-author DOI 10.1007/s00595-025-03188-7↗
  2. Prognostic stratification of unresectable locally advanced pancreatic cancer using a combination of inflammatory and nutritional indices: a retrospective cohor… Co-author DOI 10.1007/s00595-026-03344-7↗
  3. Preoperative predictors of early recurrence after neoadjuvant gemcitabine plus S-1 in resectable pancreatic cancer: a multicenter study. Co-author DOI 10.1007/s00595-026-03416-8↗
  4. Abdominal aortic calcification volume as a preoperative prognostic predictor for pancreatic cancer. Co-author DOI 10.1007/s00595-024-02882-2↗
  5. The minimum apparent diffusion coefficient value on preoperative magnetic resonance imaging in resectable pancreatic cancer: a new prognostic factor for biolog… Co-author DOI 10.1007/s00595-025-03050-w↗
  6. The preoperative cachexia index predicts outcomes after pancreatic resection for resectable pancreatic cancer. Co-author DOI 10.1007/s00595-025-03088-w↗
  7. Signal heterogeneity in apparent diffusion coefficient map of magnetic resonance imaging in resectable pancreatic cancer: a new prognostic factor for biologica… Co-author DOI 10.1016/j.suronc.2025.102270↗
  8. The Significant Impact of Fibrinogen-C-Reactive Protein-Albumin Ratio on the Long-Term Outcomes After Pancreatic Resection for Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002416↗
  9. Prognostic Impact of a Decrease in Serum Carbohydrate Antigen 19-9 Levels After Preoperative Therapy for 4 Months or More for Borderline Resectable Pancreatic … Co-author DOI 10.1177/00031348241278016↗
  10. Changes in Skeletal Muscle Volume During Preoperative Chemotherapy Affect the Outcome of Pancreatic Cancer. Co-author DOI 10.1177/00031348241278021↗
  11. Prognostic impact of osteosarcopenia in patients undergoing pancreatic resection for pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00423-024-03315-x↗
  12. Prognostic significance of occult vertebral fracture in patients undergoing pancreatic resection for pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.01.003↗
  13. The prognosis-based classification model in resectable pancreatic cancer. Co-author DOI 10.1016/j.suronc.2024.102035↗
  14. Effect of Risk Factor Score on Early Recurrence After Pancreatectomy for Invasive Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.16968↗
  15. Effect of Chemoradiotherapy on Locoregional Recurrence After Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17229↗
  16. Systemic inflammation adversely affects response to anamorelin in patients with pancreatic cancer. Co-author DOI 10.1007/s00520-023-08206-3↗
  17. Superior mesenteric vein/portal vein contact in preoperative imaging indicates biological malignancy in anatomically resectable pancreatic cancer. First author DOI 10.1016/j.suronc.2023.101998↗
  18. The Impact of Fibrinogen to Prognostic Nutritional Index Rate on Prognosis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1177/00031348231204912↗
  19. Successful resection of port site recurrence of pancreatic ductal adenocarcinoma after laparoscopic distal pancreatectomy. Co-author DOI 10.1186/s40792-023-01607-w↗
  20. Preoperative Therapy for Unresectable Locally Advanced Pancreatic Cancer for ≥6 Months Improves Prognosis After Pancreatectomy. Co-author DOI 10.21873/anticanres.16599↗
  21. The effectiveness of adjuvant chemotherapy for Stage I pancreatic cancer based on the UICC 8th edition. Co-author DOI 10.1007/s00423-022-02686-3↗
  22. Effects of an enteral nutrient-rich therapy with omega-3 fatty acids in patients with unresectable or recurrent biliary tract cancer or pancreatic cancer durin… Co-author DOI 10.1007/s12032-021-01625-4↗
  23. Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer. Co-author DOI 10.1371/journal.pone.0267623↗
  24. Practical significance of pancreatectomy with lymphadenectomy around the superior mesenteric artery for pancreatic cancer: comparison of prognosis after adjust… Co-author DOI 10.1007/s00423-021-02166-0↗
  25. The novel index using preoperative C-reactive protein and neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with pancreatic cancer. Co-author DOI 10.1007/s10147-021-01964-2↗
  26. Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001767↗
  27. Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy. Co-author DOI 10.21873/anticanres.12485↗
  28. Histopathologically proven autoimmune pancreatitis mimicking neuroendocrine tumor or pancreatic cancer. Co-author DOI 10.1159/000336199↗
  29. Desensitization of NFκB for overcoming chemoresistance of pancreatic cancer cells to TNF-α or paclitaxel. Co-author PMID 23155247↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toru Ikegami · 25 shared papers, 2021–2026 · strength 5.09
  2. Kenei Furukawa · 25 shared papers, 2021–2026 · strength 5.02
  3. Yoshihiro Shirai · 23 shared papers, 2021–2026 · strength 4.66
  4. Koichiro Haruki · 21 shared papers, 2018–2026 · strength 4.39
  5. Masashi Tsunematsu · 18 shared papers, 2022–2026 · strength 3.90
  6. Michinori Matsumoto · 15 shared papers, 2023–2026 · strength 3.23
  7. Takeshi Gocho · 16 shared papers, 2018–2026 · strength 2.89
  8. Ryoga Hamura · 13 shared papers, 2021–2026 · strength 2.33
  9. Mitsuru Yanagaki · 10 shared papers, 2021–2026 · strength 2.20
  10. Tadashi Uwagawa · 12 shared papers, 2018–2026 · strength 2.09
  11. Norimitsu Okui · 8 shared papers, 2023–2026 · strength 1.79
  12. Taro Sakamoto · 8 shared papers, 2018–2026 · strength 1.45
  13. Yoshiaki Tanji · 6 shared papers, 2023–2026 · strength 1.26
  14. Tomohiko Taniai · 6 shared papers, 2021–2026 · strength 1.25
  15. Kyohei Abe · 7 shared papers, 2018–2025 · strength 1.22
  16. Tadashi Uwagawa · 4 shared papers, 2024–2025 · strength 0.95
  17. Yosuke Igarashi · 4 shared papers, 2023–2025 · strength 0.85
  18. Yuta Yamada · 3 shared papers, 2024–2026 · strength 0.74
  19. Hironori Shiozaki · 4 shared papers, 2021–2024 · strength 0.60
  20. Hiroaki Shiba · 4 shared papers, 2021–2022 · strength 0.54
  21. Katsuhiko K. Yanaga · 5 shared papers, 2012–2022 · strength 0.43
  22. Shunta Ishizaki · 2 shared papers, 2023–2024 · strength 0.39
  23. Shuichi Fujioka · 4 shared papers, 2012–2023 · strength 0.36
  24. Takashi Aida · 1 shared paper, 2023 · strength 0.19
  25. Yuki Fujiwara · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.